Zai Lab's Zocilurtatug Pelitecan Shows Promising Results in Treating Small Cell Lung Cancer with Brain Metastases
Zai Lab Limited has announced new clinical data demonstrating the efficacy of Zocilurtatug Pelitecan (Zoci), a DLL3-targeting antibody-drug conjugate, in treating extensive stage small cell lung cancer (ES-SCLC) with brain metastases. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, shows a confirmed intracranial objective response rate of 53.7% among patients, with notable activity regardless of prior intracranial radiotherapy. Zoci also showed promising results in treating extrapulmonary neuroendocrine carcinomas (NECs), with a 38.2% confirmed objective response rate. The ongoing global Phase 3 trial aims to advance Zoci towards registrational phase by the end of 2026. 
